Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (Nasdaq: MNKD) announced a significant breakthrough in diabetes management at the ATTD 2022 conference. A proof-of-concept study revealed that a simplified 2x dose of Technosphere® Insulin (TI) resulted in a mean difference of 52 mg/dL in post-prandial glucose excursions (PPGE) at 120 minutes compared to the standard dosage, showing enhanced efficacy without new safety concerns. This approach may improve glycemic control for diabetes patients and could influence future dosing recommendations.
United Therapeutics announced positive results from the BREEZE study evaluating Tyvaso DPI in patients with pulmonary arterial hypertension (PAH). The study showed safety in transitioning from Tyvaso to Tyvaso DPI with no serious adverse events. Improvements in six-minute walk distance by 11.5 meters and patient satisfaction were reported. Long-term safety data from an optional extension phase indicated continued efficacy. FDA action on the New Drug Application for Tyvaso DPI is anticipated by
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually from April 4-7, 2022. The company's presentation will be available on April 4 at 11:00 am ET and can be accessed on their website, with an archived version for later viewing. Management will also be available for one-on-one meetings during the event. MannKind focuses on developing inhaled therapies, including the FDA-approved Afrezza® inhalation powder, which is the first ultra-rapid-acting mealtime insulin in the U.S.
MannKind Corporation (Nasdaq: MNKD) announced that Chief Scientific Officer Thomas Hofmann will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29, 2022, at 8:00 AM PT. The company specializes in developing inhaled therapeutic products for endocrine and orphan lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only FDA-approved inhaled ultra-rapid-acting mealtime insulin available in the U.S. by prescription.
MannKind Corporation (Nasdaq: MNKD) will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:00 pm (ET). CEO Michael Castagna will deliver a virtual presentation accessible via the company’s website. MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, notably commercializing Afrezza® (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting mealtime insulin in the U.S. The webcast will be available for 14 days post-event.
MannKind Corporation (Nasdaq: MNKD) reported total revenues of $75.4 million for 2021, marking a 16% increase from 2020. Fourth quarter net revenue from Afrezza reached $11.3 million, up 13% year-over-year. Cash and investments stood at $260.7 million as of December 31, 2021. However, the company faced challenges, including a net loss of $80.9 million for the year and a significant increase in SG&A and R&D expenses. The review deadline for Tyvaso DPI has been extended to May 2022, impacting future revenue potential.
MannKind Corporation (Nasdaq: MNKD) announced that the FDA issued an information request to United Therapeutics regarding the New Drug Application for Tyvaso DPI. This request pertains to additional information on the pulmonary safety of the product, linked to a Citizen Petition. The FDA now considers the response a major amendment, extending the review deadline to May 2022. MannKind will discuss its 2021 financial results and updates in a conference call on February 24, 2022. Tyvaso DPI remains investigational and is not approved for any use.
MannKind Corporation (Nasdaq: MNKD) is set to release its 2021 fourth quarter and full year financial results on February 24, 2022, at 5:00 p.m. Eastern Time. The call will feature CEO Michael Castagna and CFO Steven Binder, discussing key financial outcomes and corporate updates. MannKind focuses on inhaled therapeutic products, notably the FDA-approved Afrezza®, an ultra rapid-acting mealtime insulin available nationwide in the U.S. and Brazil through partner Biomm SA.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 PM (ET). Interested parties can access the webcast through the Company’s website. MannKind is known for developing inhaled therapeutic products, including Afrezza®, an FDA-approved inhaled insulin that is available in the U.S. and Brazil. The webcast will be available for 14 days post-event.
MannKind Corporation (Nasdaq: MNKD) has announced that its CEO, Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference. The presentation will be available on demand starting January 10, 2022. Interested individuals can find the webcast link in the Events & Presentations section of the company’s website, where it will remain accessible for 14 days post-event.
The company specializes in inhaled therapeutic products for endocrine and orphan lung diseases, with its flagship product being Afrezza, the only inhaled ultra rapid-acting mealtime insulin in the U.S.
